209
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Leukapheresis Does Not Improve Early Survival Outcome of Acute Myeloid Leukemia with Leukostasis Patients – A Dual-Center Retrospective Cohort Study

, , & ORCID Icon
Pages 623-633 | Published online: 14 Jul 2021

References

  • Giammarco S, Chiusolo P, Piccirillo N, et al. Hyperleukocytosis and leukostasis: management of a medical emergency. Expert Rev Hematol. 2017;10(2):147–154. doi:10.1080/17474086.2017.1270754
  • Ganzel C, Becker J, Mintz PD, Lazarus HM, Rowe JM. Hyperleukocytosis, leukostasis and leukapheresis: practice management. Blood Rev. 2012;26(3):117–122. doi:10.1016/j.blre.2012.01.003
  • Ali A, Mirrakhimov A, Abboud  C, Cashen A. Leukostasis in adult acute hyperleukocytic leukemia: a clinician’s digest. Hematol Oncol. 2016;34(2):69–78. doi:10.1002/hon.2292
  • Korkmaz S. The management of hyperleukocytosis in 2017: do we still need leukapheresis? Transfus Apher Sci. 2018;57(1):4–7. doi:10.1016/j.transci.2018.02.006
  • Barrett CL, Louw VJ, Webb MJ. Exchange transfusion as a life-saving intervention in three patients with different haematological malignancies with severe hyperleukocytosis where leukapheresis was not available. Transfus Apher Sci. 2013;49(3):397–402.
  • Aqui N, O’Doherty U. Leukocytapheresis for the treatment of hyperleukocytosis secondary to acute leukemia. Hematology Am Soc Hematol Educ Program. 2014;2014(1):457–460. doi:10.1182/asheducation-2014.1.457
  • Porcu P, Cripe LD, Ng EW, et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma. 2000;39(1–2):1–18. doi:10.3109/10428190009053534
  • Howard SC, Jones DP, Pui C-H. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844–1854. doi:10.1056/NEJMra0904569
  • Aslam HM, Zhi C, Wallach SL. Tumor lysis syndrome: a rare complication of chemotherapy for metastatic breast cancer. Cureus. 2019;11(2):e4024. doi:10.7759/cureus.4024.
  • Pastore F, Pastore A, Wittmann G, Hiddemann W, Spiekermann K, Winn RA. The role of therapeutic leukapheresis in hyperleukocytotic AML. PLoS One. 2014;9(4):7–10. doi:10.1371/journal.pone.0095062
  • Singh N, Lubana SS, Dabrowski L, Sidhu G. Leukostasis in chronic lymphocytic leukemia. Am J Case Rep. 2020;21:1–5. doi:10.12659/AJCR.924798
  • Röllig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood. 2015;125(21):3246–3252. doi:10.1182/blood-2014-10-551507
  • Porcu P, Farag S, Marcucci G, Cataland SR, Kennedy MS, Bissell M. Leukocytoreduction for acute leukemia. Ther Apher. 2002;6(1):15–23. doi:10.1046/j.1526-0968.2002.00402.x
  • Ventura GJ, Hester JP, Smith TL, Keating MJ. Acute myeloblastic leukemia with hyperleukocytosis: risk factors for early mortality in induction. Am J Hematol. 1988;27(1):34–37. doi:10.1002/ajh.2830270109
  • Giles FJ, Shen Y, Kantarjian HM, et al. Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival. Leuk Lymphoma. 2001;42(1–2):67–73. doi:10.3109/10428190109097677
  • Bug G, Anargyrou K, Tonn T, et al. Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis. Transfusion (Paris). 2007;47(10):1843–1850. doi:10.1111/j.1537-2995.2007.01406.x
  • Malkan UY, Ozcebe OI. Leukapheresis do not improve early death rates in acute myeloid leukemia patients with hyperleukocytosis. Transfus Apher Sci. 2017;56(6):880–882. doi:10.1016/j.transci.2017.11.002
  • Shallis RM, Stahl M, Wei W, et al. Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. Leuk Lymphoma. 2020;61(5):1220–1225. doi:10.1080/10428194.2020.1728753
  • Nan X, Qin Q, Gentille C, et al. Leukapheresis reduces 4-week mortality in acute myeloid leukemia patients with hyperleukocytosis–a retrospective study from a tertiary center. Leuk Lymphoma. 2017;58(9):2110–2117. doi:10.1080/10428194.2016.1277386
  • Malkan UY, Gunes G, Eliacik E, et al. The factors affecting early death after the initial therapy of acute myeloid leukemia. Int J Clin Exp Med. 2015;8(12):22564–22569.
  • Stahl M, Shallis RM, Wei W, et al. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a Large, Retrospective, Multicenter, International Study. Leukemia. 2020;34(12):3149–3160. doi:10.1038/s41375-020-0783-3
  • Bewersdorf JP, Zeidan AM. Hyperleukocytosis and leukostasis in acute myeloid leukemia: can a better understanding of the underlying molecular pathophysiology lead to novel treatments? Cells. 2020;9(10):2310. doi:10.3390/cells9102310
  • Stucki A, Rivier A-S, Gikic M, Monai N, Schapira M, Spertini O. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood. 2001;97(7):2121–2129. doi:10.1182/blood.V97.7.2121
  • McKee LC, Collins RD. Intravascular leukocyte thrombi and aggregates as a cause of morbidity and mortality in leukemia. Medicine (Baltimore). 1974;53(6):463–478. doi:10.1097/00005792-197411000-00006
  • Zuckerman T, Ganzel C, Tallman MS, Rowe JM. How I treat hematologic emergencies in adults with acute leukemia. Blood. 2012;120(10):1993–2002. doi:10.1182/blood-2012-04-424440
  • Langleben D, Orfanos SE, Giovinazzo M, et al. Pulmonary capillary surface area in supine exercising humans: demonstration of vascular recruitment. Am J Physiol Lung Cell Mol Physiol. 2019;317(3):L361–8. doi:10.1152/ajplung.00098.2019
  • Cavenagh JD, Gordon-Smith EC, Gibson FM, Gordon MY. Acute myeloid leukaemia blast cells bind to human endothelium in vitro utilizing E-selectin and vascular cell adhesion molecule-1 (VCAM-1). Br J Haematol. 1993;85(2):285–291. doi:10.1111/j.1365-2141.1993.tb03168.x
  • Hölig K, Moog R. Leukocyte depletion by therapeutic leukocytapheresis in patients with leukemia. Transfus Med Hemother. 2012;39(4):241–245. doi:10.1159/000341805
  • Jin Y, Guo S, Cui Q, et al. A hospital based retrospective study of factors influencing therapeutic leukapheresis in patients presenting with hyperleukocytic leukaemia. Sci Rep. 2018;8:294. doi:10.1038/s41598-017-17534-4
  • Hoffman R, Benz E, Silberstein L, et al. Hematology: Basic Principles and Practice. 7th ed. Elsevier; 2017:924–953.
  • Davenport A, Tolwani A. Citrate anticoagulation for continuous renal replacement therapy (CRRT) in patients with acute kidney injury admitted to the intensive care unit. NDT Plus. 2009;2(6):439–447. doi:10.1093/ndtplus/sfp136
  • Shelat SG. Practical considerations for planning a therapeutic apheresis procedure. Am J Med. 2010;123(9):777–784. doi:10.1016/j.amjmed.2010.01.022
  • Schwartz J, Winters JL, Padmanabhan A, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American Society for apheresis: the sixth special issue. J Clin Apher. 2013;28(3):145–284. doi:10.1002/jca.21276
  • Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice – evidence-based approach from the writing committee of the American Society for apheresis: the eighth special issue. J Clin Apher. 2019;34(3):171–354.
  • Makroo RN, Kakkar B, Chowdhry M, Agrawal S, Seth S, Thakur UK. Therapeutic leukapheresis in a tertiary care hospital: a case series. Asian J Transfus Sci. 2017;11(1):65–68. doi:10.4103/0973-6247.200772
  • Choi MH, Choe YH, Park Y, et al. The effect of therapeutic leukapheresis on early complications and outcomes in patients with acute leukemia and hyperleukocytosis: a Propensity Score-Matched Study. Transfusion (Paris). 2018;58(1):208–216. doi:10.1111/trf.14329
  • Göçer M, Kurtoğlu E. Effect of prophylactic leukapheresis on early mortality and overall survival in acute leukemia patients with hyperleukocytosis. Ther Apher Dial. 2021. doi:10.1111/1744-9987.13645
  • Bewersdorf JP, Giri S, Tallman MS, Zeidan AM, Stahl M. Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia—a systematic review and meta-analysis. Transfusion (Paris). 2020;60(10):2360–2369. doi:10.1111/trf.15994
  • Triyono T, Hans V. Therapeutic apheresis in Asia: an Indonesia single center experience. J Clin Apher. 2014;28(April 2013):349–355.
  • de Jonge HJM, Valk PJM, de Bont ESJM, et al. Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD. Haematologica. 2011;96(9):1310–1317. doi:10.3324/haematol.2011.040592
  • Padilha SL, Matos MCC, Domino NR, Domino NR. Acute myeloid leukemia: survival analysis of patients at a university hospital of Paraná. Rev Bras Hematol Hemoter. 2015;37(1):21–27. doi:10.1016/j.bjhh.2014.11.008
  • Liu C, Hong Y, Kuan AS, et al. The risk of early mortality in elderly patients with newly diagnosed acute myeloid leukemia. Cancer Med. 2020;9(4):1572–1580. doi:10.1002/cam4.2740
  • Kuo KHM, Callum JL, Panzarella T, et al. A retrospective observational study of leucoreductive strategies to manage patients with acute myeloid leukaemia presenting with hyperleucocytosis. Br J Haematol. 2015;168(3):384–394. doi:10.1111/bjh.13146
  • Kantarjian H, Ravandi F, O’Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010;116(22):4422–4429. doi:10.1182/blood-2010-03-276485
  • Malfuson J-V, Etienne A, Turlure P, et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica. 2008;93(12):1806–1813. doi:10.3324/haematol.13309
  • Malkawi A, Anand A, Al-Ameri A, Abdelfatah M, Kanaan Z, Haller N. Outcome of patients with acute myeloid leukemia/high risk MDS according to the kidney function. Blood. 2013;122(21):5007. doi:10.1182/blood.V122.21.5007.5007
  • Dhakal P, Lyden E, Lee A, et al. Effects of obesity on overall survival of adults with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2020;20(3):e131–6. doi:10.1016/j.clml.2019.11.001
  • Navarro WH. Impact of obesity in the setting of high-dose chemotherapy. Bone Marrow Transplant. 2003;31(11):961–966. doi:10.1038/sj.bmt.1704052
  • Kendrick J, Warkentin D, Ensom MHH. The impact of obesity on pharmacokinetics and dosing of leukemia chemotherapy. In: Mittelman SD, Berger NA, editors. Energy Balance and Hematologic Malignancies [Internet]. Boston, MA: Springer US; 2012:97–127. Energy Balance and Cancer. doi:10.1007/978-1-4614-2403-1_5